AtriCure (ATRC) Misses Q4 EPS by 13c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
AtriCure Inc. (ATRC) PT Raised to $57 at BTIG
February 13, 2025 5:21 AM ESTBTIG analyst Marie Thibault raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $57.00 (from $53.00) while maintaining a Buy rating.
The analyst comments "AtriCure announced Q4 revenue of $124.3M (+16.6% y/y rep, +16.7% y/y cc), in line with the preliminary announcement last month. This result came in above the implied Q4 guidance range of $118M-$121M, beating consensus and our forecast of $119.8M at the time of the pre-announcement. U.S.... More
